ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Varenicline

Also written as “varenicline”, “Varenicline Tartrate” and “varenicline (CP-526,555)”.

Its studies are mostly in Smoking Cessation · Dry Eye Syndromes · Smoking · Trigeminal Neuralgia · Cigarette Smoking, led by 6 companies.

Drug pageVarenicline: every studyMany companies study it; this page follows only the 44 they lead. All 254 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 3, 200844 company-led studies, 1 open or runningNext primary completion: Feb 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only320 open or runningphase 4since Jan 3, 2008Aug 29, 2005none ahead
Viatrisits history only60 open or runningphase 3since Jul 25, 2019Aug 15, 2018none ahead
Corxel Pharmaceuticalsits history only20 open or runningphase 3since May 13, 2022May 13, 2022none ahead
Rose Research Centerits history only20 open or runningphase 4since Jun 6, 2019Jun 6, 2019none ahead
Kriya Therapeutics11 open or runningphase 2since Apr 17, 2026Apr 17, 2026Feb 2029phase 2 · NCT07596485
SRI Internationalits history only10 open or runningno phasesince Mar 8, 2006Mar 8, 2006none ahead

Also a collaborator on its studies: GlaxoSmithKline.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kriya Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2026First study: phase 2 study in Trigeminal NeuralgiaFirst studyNCT07596485 · 24 planned · Canada

Ahead

  1. Feb 2029Primary completion: phase 2 study in Trigeminal NeuralgiaNCT07596485

TargetBeta

“Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cytisineruleAchieve Life Sciencesphase 313

Studies

The one study Kriya Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07596485Trigeminal Neuralgia · Canada2RecruitingFeb 202924

How it is read

Names in the registry

  • “varenicline”, 11 entries
  • “Varenicline Tartrate”, 7 entries
  • “Varenicline”, 6 entries
  • “varenicline (CP-526,555)”, 6 entries
  • “CP-526,555 (varenicline)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.